NCT00224146已完成4 期
Multicenter Assessment of Transdermal Therapy in Overactive Bladder With Oxybutynin TDS (MATRIX)
Watson Pharmaceuticals10 个研究点 分布在 1 个国家目标入组 2,878 人开始时间: 2004年5月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 2,878
- 试验地点
- 10
- 主要终点
- Change in health-related quality of life
研究概览
简要总结
This study evaluates changes in health related quality of life outcomes in patients using Oxytrol(r)
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult patients with one or more symptom of overactive bladder, including urge urinary incontinence, urgency and/or frequency
排除标准
- •Patients for whom Oxytrol(r) is contraindicated.
- •Patients treated with Oxytrol(r) prior to participation in this study.
- •Patients residing in long-term care facilities or nursing homes.
结局指标
主要结局
Change in health-related quality of life
次要结局
- Change in other outcomes such as:
- depression
- work productivity
- participant satisfaction
- effect of enhanced patient education on any of the above outcomes
研究者
研究点 (10)
Loading locations...
相似试验
已完成
3 期
Study to Gather Information About the Actual Use of an Adhesive Patch Placed on the Skin to Deliver Oxytrol Through the Skin Into the Bloodstream.Overactive BladderNCT04534491Bayer855
Unknown
不适用
Oxygen for Vascular Incisional HealingSurgical Wound HealingLower ExtremityRevascularizationIncisionNCT03746132Neogenix, LLC dba Ogenix100
Unknown
不适用
Cyclical Topical Wound Oxygen Therapy (TWO2) in the Treatment of Chronic WoundsEvaluate the Efficacy of Cyclical Topical Wound Oxygen Therapy in the Treatment of Chronic WoundsNCT04168905Second Affiliated Hospital, School of Medicine, Zhejiang University192
已完成
3 期
Rebif New Formulation (RNF) Quality of Life (QOL) StudyRelapsing Multiple SclerosisNCT00472797EMD Serono232
已完成
3 期
Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHTOpen Angle GlaucomaOcular HypertensionNCT02914509Ocular Therapeutix, Inc.565